The potential for artificially intelligence-assisted bioweapon development dominated discussions at this year’s Munich Security Conference, according to Sania Nishtar, leader of Gavi, the Vaccine Alliance. Nishtar highlighted a radical lowering of the barrier to entry for creating genetically engineered bioweapons, fueled by advances in AI-enabled gene editing.
The concern isn’t solely focused on state actors. Nishtar noted the prospect of bioweapons being developed by non-state actors as a key driver of renewed urgency in multilateral pandemic preparation and response efforts. This assessment aligns with growing anxieties expressed in the biosecurity community regarding the accessibility of tools for creating dangerous pathogens.
While the public health response remains focused on mitigating the impact of infectious threats regardless of their origin—natural, accidental, or deliberate—the increasing role of AI introduces a new layer of uncertainty. Policymakers are now assessing existing capacities and identifying necessary enhancements for detecting and responding to these evolving threats.
The rapid advancement of AI is outpacing the development of appropriate regulatory frameworks, creating gaps in governance related to biological weapons, according to a recent report. This lag in regulation raises concerns about the potential for misuse of AI technologies in the life sciences.
Concerns extend to AI’s ability to design toxins that can evade existing safety checks used by companies screening for potential bioweapons. A report from Science detailed how AI-designed toxins have slipped through these safeguards, potentially violating the Biological Weapons Convention, which prohibits the development or production of such weapons.
Gavi, the Vaccine Alliance, has publicly acknowledged the threat, posting on social media platforms about the lowered barrier to developing genetically engineered bioweapons. The organization, led by Nishtar, is actively involved in discussions surrounding global health security and pandemic preparedness.
Despite international agreements addressing biological weapons, the speed of AI development presents a significant challenge. The funding model supporting critical health-security safeguards is also facing challenges, potentially hindering the ability to adequately prepare for and respond to AI-enabled bioweapons threats.
